Corcept Therapeutics Incorporated (CORT)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	140,686	141,295	125,983	118,023	106,140	91,386	94,616	94,500	101,418	116,870	112,733	111,844	112,512	106,453	97,607	99,411	106,011	109,398	114,113	105,972
Total stockholders’ equity	US$ in thousands	679,589	638,835	596,243	547,864	506,705	461,679	421,614	529,584	501,842	473,364	442,326	407,811	375,806	540,229	522,675	510,802	523,338	489,680	453,698	409,489
ROE		20.70%	22.12%	21.13%	21.54%	20.95%	19.79%	22.44%	17.84%	20.21%	24.69%	25.49%	27.43%	29.94%	19.71%	18.67%	19.46%	20.26%	22.34%	25.15%	25.88%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $140,686K ÷ $679,589K
= 20.70%

Corcept Therapeutics Incorporated's return on equity (ROE) has shown some fluctuations over the period from March 2020 to December 2024.

The ROE started at a relatively high level of 25.88% in March 2020 and maintained a similar range until September 2021, with a slight decrease over time. This signifies that the company was efficiently utilizing its equity to generate profits during this period.

However, from December 2021 onwards, there was a notable increase in ROE, reaching a peak of 29.94% in December 2021. This suggests that the company might have improved its profitability or optimized its capital structure during that quarter.

Subsequently, the ROE experienced a decline in the following quarters, dropping to around 17.84% in March 2023, before recovering and stabilizing between 20-22% from June 2023 to December 2024. This indicates that the company's profitability and efficiency in generating returns for its equity holders became more consistent during this time frame.

Overall, Corcept Therapeutics Incorporated's ROE performance reflects both periods of strong profitability and moments of fluctuation, with the company demonstrating the ability to adjust and maintain reasonable returns on its equity capital.